Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis
Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis
复制标题
DOI：
10.1177/1352458517699876
复制
发表时间：
2018-04-01
影响因子：
5.8
通讯作者：
Perumal, Jai S.
中科院分区：
文献类型：
--
作者：
Ranganathan, Usha;Kaunzner, Ulrike;Perumal, Jai S.
背景：阿仑单抗是一种获批用于复发缓解型多发性硬化症（RRMS）的单克隆抗体。尽管免疫性血小板减少症（ITP）已被报道为阿仑单抗输注后的继发性自身免疫现象，但尚未报道输注期间立即出现血小板减少症。目的：我们报告了阿仑单抗第一个疗程期间出现的短暂、可逆、自限性急性血小板减少症。结果和结论：在Alemtuzumab的最初5天疗程中，22例患者中共有3例发生轻度自限性瘀伤，与血小板计数较基线下降相关。在病历审查时，所有22例接受Alemtuzumab治疗的患者均发生了血小板计数立即下降（大多无症状），并在输注后2个月内恢复正常。
Background: Alemtuzumab is a monoclonal antibody approved for relapsing-remitting multiple sclerosis (RRMS). Although Immune thrombocytopenia (ITP) has been reported as a secondary autoimmune phenomenon following alemtuzumab infusion, immediate thrombocytopenia during the infusion has not been reported.Objective: We report transient, reversible, self-limiting acute-onset thrombocytopenia during the first course with alemtuzumab.Results and conclusion: In total, 3 of 22 paitents developed mild self-limited bruising associated with a drop in platelet count from their baseline during the intial 5-day course of alemtuzumab. Upon chart review, all 22 patients who received alemtuzumab developed an immediate mostly asymptomatic drop in platelet count which returned to normal within 2months post-infusion.